New developments in sustained release drug delivery for the treatment of intraocular disease - Wikidata - wikimedia - TriplyDB

New developments in sustained release drug delivery for the treatment of intraocular disease

New developments in sustained release drug delivery for the treatment of intraocular disease

http://www.wikidata.org/entity/Q33760311

about

An overview of clinical and commercial impact of drug delivery systems Enhancement of scleral macromolecular permeability with prostaglandins Contact dermatitis from topical antiviral drugs.Periocular routes for retinal drug delivery.Novel approaches to retinal drug delivery.Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs.Novel engineered systems for oral, mucosal and transdermal drug delivery.Distribution of Triamcinolone Acetonide after Intravitreal Injection into Silicone Oil-Filled Eye Development of biodegradable controlled release scleral systems of triamcinolone acetonide.Gellan-based scleral implants of indomethacin: in vitro and in vivo evaluation.Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes.Chitosan electrodeposition for microrobotic drug delivery.Electroforming of implantable tubular magnetic microrobots for wireless ophthalmologic applications.PDMS embedded microneedles as a controlled release system for the eye

P2860

Q27007143-7A9C30AE-9DB0-48A4-9868-60A0F9252121 Q28345276-C44AB157-2E28-475D-BAFB-41E75139E548 Q34216587-C3015DF7-7A2E-4958-9245-DF111954EBDC Q36316631-BCE2E7CD-1FE9-4E70-8AFD-B032F5164FB9 Q36903801-9897413D-3AF3-48E7-85D4-1E8630385DAE Q37769529-43E598F0-65DF-415D-835B-01AA5143DF82 Q38122744-287819D0-C9CB-4B65-80A5-8CC653EFEEC8 Q42398866-43DD320F-9E02-48ED-90FB-D4B9A6541EEE Q42881021-0EB98637-BF04-4EDC-AD2C-E12A804E55EA Q45286819-5F5EECFF-4B64-4CA0-B500-5330FB83A818 Q45823132-CFDC6A1D-2493-4C9E-8D45-A27BF73A876E Q50484799-C1513BB2-9EE0-4FB1-B9B5-51DA787E9842 Q51071008-C3097824-D01B-47BC-9F12-7514AFB92EE0 Q57147707-2FA6D11C-4A17-4F26-BDF6-8642176D92EB

P2860

New developments in sustained release drug delivery for the treatment of intraocular disease

http://www.wikidata.org/entity/Q33760311

description

1999 nî lūn-bûn

@nan

1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年学术文章

@wuu

1999年学术文章

@zh-cn

1999年学术文章

@zh-hans

1999年学术文章

@zh-my

1999年学术文章

@zh-sg

1999年學術文章

@yue

name

New developments in sustained ...... eatment of intraocular disease

@ast

New developments in sustained ...... eatment of intraocular disease

@en

type

label

New developments in sustained ...... eatment of intraocular disease

@ast

New developments in sustained ...... eatment of intraocular disease

@en

prefLabel

New developments in sustained ...... eatment of intraocular disease

@ast

New developments in sustained ...... eatment of intraocular disease

@en

P1433

Q33760311-F61D197E-5266-4959-9A44-997FA98501DF

P1476

Q33760311-65FA6A36-E516-427A-8946-FFB80F2EACCE

P2093

Q33760311-10A9BECD-2428-49C3-BE8C-FA2443808DF4

Q33760311-13F566C1-7AAC-46C7-B8AE-B64E5CF5566E

P2860

Q33760311-05429FE8-6AC9-49B8-82C2-4D9558765375

Q33760311-0A1910C1-B427-4DF8-93B8-B43108E33552

Q33760311-0F33C184-5DEA-4CC6-A8DE-28BBA9E87F33

Q33760311-271B4C4C-94D5-4082-A5B3-5BC88190FEB9

Q33760311-2B9E1F79-4E3F-432B-AD1B-562A72544907

Q33760311-39C1014E-5BA5-4B91-9D20-7C652FF31C51

Q33760311-43CEEB99-E6F3-46F6-B54D-D5D3236338C9

Q33760311-43FC297C-3CB4-4D05-9AB1-BE036743EA40

Q33760311-454783F7-3972-4B76-B32D-D25A5E20898E

Q33760311-48A6B2D0-C229-47E2-ACBB-84803BC5D87A

P304

Q33760311-5B966906-9E7A-4EFF-8A91-02A5683292FE

P31

Q33760311-C0E44BE2-9DD3-45FC-AD5C-DED122DA180C

P356

Q33760311-773641AF-1663-483F-964B-41AC0FC6CD41

P407

Q33760311-4A28B21B-AB8A-4AA7-AF9F-CD07C0371FDE

P433

Q33760311-8B9413F9-605B-4C4B-88FF-E2150AC56168

P478

Q33760311-C551C6F0-40A1-4CE1-978C-696D4F3B8B7D

P577

Q33760311-820C60FC-CE3D-46EB-90D0-124A13D07FFF

P5875

Q33760311-0A730644-6B87-4BC1-97EF-FF6E9D77E7F6

P698

Q33760311-29E8F283-BF42-461F-9DF1-C21378AEF8DF

P921

Q33760311-E6E0D547-3A17-4B75-B38B-C6820695FF4C

P932

Q33760311-4CB72C24-470D-43C7-9A1B-E702DE7E0701

P356

P1433

British Journal of Ophthalmology

P1476

New developments in sustained ...... eatment of intraocular disease

@en

P2093

Velez G

http://www.w3.org/2001/XMLSchema#string

Whitcup SM

http://www.w3.org/2001/XMLSchema#string

P2860

Intravitreal toxicology in rabbits of two preparations of 1-O-octadecyl-sn-glycerol-3-phosphonoformate, a sustained-delivery anti-CMV drug

Effects of nilvadipine, a calcium antagonist, on rabbit ocular circulation and optic nerve head circulation in NTG subjects.

Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy.

Ocular penetration of cyclosporin A. III: The human eye

Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.

The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter

Intravitreal drug therapy.

Factors affecting the intraocular penetration of antibiotics. The influence of route, inflammation, animal species and tissue pigmentation.

The clinical pharmacology of methotrexate: new applications of an old drug.

The blood-ocular barriers.

P304

1225-1229

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BJO.83.11.1225

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P577

1999-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12764498

http://www.w3.org/2001/XMLSchema#string

P698

10535845

http://www.w3.org/2001/XMLSchema#string

P921

P932

1722856

http://www.w3.org/2001/XMLSchema#string